GBR-13098 is a psychostimulant and selective dopamine uptake inhibitor.[1]
Names | |
---|---|
IUPAC name
1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-[3-(4-fluorophenyl)propyl]piperazine;methanesulfonic acid
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C30H39F3N2O7S2 | |
Molar mass | 660.76 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Blocking the endogenous striatal dopamine (DA) transporter with GBR-13098 in mice has been shown to prevent damage to the DA nerve terminals caused by malonate. It was suggested that DA transporter inhibitors like GBR-13098 could be used to prevent or treat neurodegenerative disorders caused by the effect of mitochondrial dysfunction on DA homeostasis.[2]
See also
editReferences
edit- ^ Pileblad E, and Engberg G. (Dec 1986). "GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies". Naunyn-Schmiedeberg's Arch Pharmacol. 334 (4): 383–7. doi:10.1007/BF00569374. PMID 2950328. S2CID 4685374.
- ^ Moy LY; et al. (Feb 2007). "Mitochondrial stress-induced dopamine efflux and neuronal damage by malonate involves the dopamine transporter". J Pharmacol Exp Ther. 320 (2): 747–56. doi:10.1124/jpet.106.110791. PMID 17090704. S2CID 9886591.